Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.35 |
| ▸ | USP2 | O75604 | 5/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27281477 | 1.00 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2CYP3A4CYP1A2USP2 | |
| SCHEMBL27282020 | 1.00 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2CYP3A4CYP1A2USP2 | |
| SCHEMBL26650708 | 0.88 | CYP3A4 (0.40) | CYP2D6SMN1; SMN2CYP3A4CYP1A2USP2 | |
| SCHEMBL17108650 | 0.87 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2CYP3A4PIK3CDTSHR | |
| SCHEMBL2608963 | 0.83 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2CYP3A4CYP1A2USP2 | |
| SCHEMBL16441056 | 0.82 | PIK3CD (0.35) | CYP2D6SMN1; SMN2PIK3CDTSHR | |
| SCHEMBL12932411 | 0.80 | SIGMAR1 (0.30) | — | |
| SCHEMBL23374702 | 0.78 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2CYP3A4CYP1A2USP2 | |
| SCHEMBL3422699 | 0.78 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2CYP3A4PIK3CDTSHR | |
| SCHEMBL26860169 | 0.78 | CYP2D6 (0.40) | CYP2D6SMN1; SMN2CYP3A4CYP1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-9695144-B2 | Dibenzazepine derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| US-20170008882-A1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-01-12 | — | — | US | disclosed |
| US-20170001986-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-01-05 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| US-9493449-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2016-02-04 | — | — | US | disclosed |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-10-08 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | CYP2D6 3853/4885SMN1; SMN2 3929/4885CYP3A4 3620/4885 |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | CYP2D6 3699/4885SMN1; SMN2 3237/4885CYP3A4 2668/4885 |
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | CYP2D6 489/4885SMN1; SMN2 780/4885CYP3A4 385/4885 |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | CYP2D6 212/4885SMN1; SMN2 577/4885CYP3A4 510/4885 |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | CYP2D6 244/4885SMN1; SMN2 432/4885CYP3A4 775/4885 |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | CYP2D6 321/4885SMN1; SMN2 925/4885CYP3A4 486/4885 |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | CYP2D6 3699/4885SMN1; SMN2 3237/4885CYP3A4 2668/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | CYP2D6 4790/4885SMN1; SMN2 2366/4885CYP3A4 4808/4885 |
| US-20170001986-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | CYP2D6 227/4885SMN1; SMN2 599/4885CYP3A4 302/4885 |
| US-11697647-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | CYP2D6 4529/4885SMN1; SMN2 1041/4885CYP3A4 4737/4885 |
| US-20230265085-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | CYP2D6 4529/4885SMN1; SMN2 1041/4885CYP3A4 4737/4885 |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | TRPC4, TRPV4, TRPV1 | CYP2D6 489/4885SMN1; SMN2 780/4885CYP3A4 385/4885 |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | CYP2D6 227/4885SMN1; SMN2 599/4885CYP3A4 302/4885 |
| US-20170008882-A1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | CACNA1A, P2RX3, P2RX6 | CYP2D6 236/4885SMN1; SMN2 212/4885CYP3A4 1793/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | CYP2D6 553/4885SMN1; SMN2 1592/4885CYP3A4 2682/4885 |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | ADORA2B, P2RX2, P2RX3 | CYP2D6 293/4885SMN1; SMN2 252/4885CYP3A4 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.